Schizophrenia

Ever wonder what about the ROI on biomedical research looks like? At the Vanderbilt University School of Medicine Basic Sciences, scientists are delivering answers—by driving discoveries that are already improving human health and paving the way for tomorrow’s treatments. This 2025–26 roundup highlights some of the year’s most exciting advances, showing the extraordinary value of sustained support for biomedical science. Read More

Link List – Right Hand Column PlaceholderRefresh After Saving to Remove .link-list.jump-links{ padding-left: 0 !important; } CENTERS & INSTITUTES: Vanderbilt Center for Addiction Research (VCAR) Warren Center for Neuroscience Drug Discovery (WCNDD) Vanderbilt Brain Institute The Brain Diseases affecting the… Read More

  Link List – Right Hand Column PlaceholderRefresh After Saving to Remove .link-list.jump-links{ padding-left: 0 !important; } CENTERS & INSTITUTES: Vanderbilt Center for Addiction Research (VCAR) Warren Center for Neuroscience Drug Discovery (WCNDD) Vanderbilt Brain Institute The Brain Diseases affecting… Read More

A new potential treatment for schizophrenia discovered through the Warren Center for Neuroscience Drug Discovery at Vanderbilt University has entered phase 1 clinical trials, marking the fifth WCNDD therapeutic to advance into human testing. Read More

Bingshan Li and his lab are changing the paradigm of how geneticists can identify risk genes for schizophrenia, enabling new studies into its underlying biology and opening new doors for the development of treatments against it. Read More

What makes these results exceptional isn’t just the compounds themselves, it’s what they represent: the value of translational research grounded in real-world therapeutic goals. The partners chose to release these best-in-class tool compounds to the scientific community to accelerate further discovery. Read More

Researchers from the Warren Center for Neuroscience Drug Discovery, in collaboration with Boehringer Ingelheim, developed a compound that can treat both negative and positive symptoms of schizophrenia in rodents. The compound holds promise as an investigational tool and an inspiration for novel schizophrenia therapies. Read More

What makes these results exceptional isn’t just the compounds themselves, it’s what they represent: the value of translational research grounded in real-world therapeutic goals. The partners chose to release these best-in-class tool compounds to the scientific community to accelerate further discovery. Read More

Researchers from the Warren Center for Neuroscience Drug Discovery, in collaboration with Boehringer Ingelheim, developed a compound that can treat both negative and positive symptoms of schizophrenia in rodents. The compound holds promise as an investigational tool and an inspiration for novel schizophrenia therapies. Read More

The Warren Center for Neuroscience Drug Discovery opened its doors to the Nashville community to share firsthand the pioneering work it is conducting on Alzheimer’s disease, Parkinson’s disease, addiction, and more. Read More